ArticleClinical pharmacology and therapeutics2017
Clopidogrel pharmacogenetics: Beyond candidate genes and genome-wide association studies.
Article in Clinical pharmacology and therapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 11 citations in OpenAlex.
- Investigation of Genomic and Transcriptomic Risk Factors of Clopidogrel Response in African Americans.Clinical pharmacology and therapeutics · 2025Article
- Discovery of ancestry-specific variants associated with clopidogrel response among Caribbean Hispanics.NPJ genomic medicine · 2025Article
- PGxQA: A Resource for Evaluating LLM Performance for Pharmacogenomic QA Tasks.Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing · 2025Article
- Investigation of genomic and transcriptomic risk factors in clopidogrel response in African Americans.medRxiv : the preprint server for health sciences · 2023Article
- The Role of Global and Local Ancestry on Clopidogrel Response in African Americans.Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing · 2023Article
- A Pharmacogenetic Study ofJournal of personalized medicine · 2021Article
- Pharmacogenomic considerations for antiplatelet agents: the era of precision medicine in stroke prevention and neurointerventional practice.Cold Spring Harbor molecular case studies · 2019Review
- Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine.Journal of personalized medicine · 2018Review
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While it is well established that genetic variation is a significant contributor to interindividual variability in clopidogrel efficacy, candidate gene and genome-wide approaches have failed to reproducibly identify genetic determinants of antiplatelet response, apart from variants in CYP2C19, prompting the need for more innovative study designs. Herein, we highlight the potential benefit of exome sequencing of patients at the extremes of clopidogrel responsivity through examination of data reported in this issue of Clinical Pharmacology & Therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.